Business
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Clinical Data From Three Programs Anticipated in Next Twelve MonthsVK2809 Phase 2b VOYAGE Study Advancing;
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Conference call scheduled for 4:30 p.m. ET today\nClinical Data From Three Programs Anticipated in Next Twelve MonthsVK2809 Phase 2b VOYAGE Study Advancing; Completion of Enrollment Expected in 4Q 2022Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Ongoing; Initial Results Expected by Year-EndPhase 1b Study of VK0214 in X-ALD to Resume; Results Expected in 1H 2023SAN DIEGO, July 27, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (\"Viking\") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2022, and provided an update on its clinical pipeline and other corporate developments.\n\n \n \n \n \n \n \n\n \nHighlights from the Quarter Ended June 30, 2022, and Other Recent Events:\n\"We are excited with the progress achieved during the first half of the year, and look forward to an active second half,\" stated Brian Lian, Ph.D., chief executive officer of Viking. \"In the coming quarters we expect to reach key milestones with our clinical programs, completing enrollment in three ongoing studies, and announcing Phase 1 data for our newest clinical compound, VK2735, an internally-developed program targeting dual activation of the GLP-1 and GIP receptors. By year-end, we also anticipate completing enrollment in our VOYAGE Phase 2b study evaluating VK2809 for the treatment of NASH and fibrosis. With our VK0214 program for X-ALD, we were recently notified that the FDA's clinical hold had been lifted and we plan to resume dosing in this study in the near-term. We look forward to the data readouts from each of these programs over the next 12 months and expect the results to strengthen Viking's position as a leader in the development of best-in-class therapeutics for metabolic disorders. Critical to these activities is the cash required to advance these programs through the clinic. We ended the second quarter with $169 million in cash, which we believe provides the runway to advance each of our clinical programs into later stage development.\"\nPipeline and Corporate Highlights\nVK2809 Phase 2b VOYAGE Study Advancing; Completion of Enrollment Expected in 4Q 2022. VK2809 is an orally available small molecule agonist of the thyroid hormone receptor that possesses ...